Congress fires another salvo at Allergan’s Mohawk deal; AI outfit raises $60M for discovery effort
→ Allergan’s move to try and steer around an IPR review of its patents for its $1.5 billion drug Restasis by handing them over to an Indian tribe for safekeeping was tailor made for public controversy. And lawmakers have proved obliging. Now a bipartisan group of House members are setting up a probe of the deal, which relies on the sovereign immunity of the Saint Regis Mohawk tribe to block the IPR. Allergan CEO Brent Saunders wants this to be a fight about the IPR process — what he’s wound up with is a PR battle with almost no chance of winning.
→ Salt Lake City-based Recursion Pharmaceuticals raised $60 million for its AI work in drug discovery. Recursion says it’s building the “world’s largest biological image dataset.” Data Collective led the Series B.
→ Gilead has offered more Phase III data in support of its HIV cocktail containing bictegravir. The combo is currently under review at the FDA.